Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Testosterone replacement in opioid-induced hypogonadotrophic hypogonadism
2014-004729-42Phase 4Completed
- Sponsor
- University Hospital Odense
- Start
- Feb 2015
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in hypogonadotropic hypogonadism (HH) and opioid-induced androgen deficiency (OPIAD) comparing Nebido with Placebo (2 arms). Primary endpoint: Body composition. Started Feb 2015; status: completed.
02
Drugs
testosterone undecanoate
03
Conditions
hypogonadotropic hypogonadism (HH)opioid-induced androgen deficiency (OPIAD)
Beyond the preview
Go deeper on 2014-004729-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004729-42.